Last reviewed · How we verify
5-METHYL-2'-FLUOROARAURACIL F-18
5-METHYL-2'-FLUOROARAURACIL F-18 is a drug. It is currently FDA-approved.
5-METHYL-2'-FLUOROARAURACIL F-18 is a marketed drug with a key composition patent expiring in 2028. The drug's market position and primary indication are not specified, but it maintains a competitive edge through its unique mechanism of action, which is currently undisclosed. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | 5-METHYL-2'-FLUOROARAURACIL F-18 |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- 18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases (EARLY_PHASE1)
- 18F-FMAU PET/CT in Imaging Patients With Advanced Cancers (NA)
- 18F-FMAU PET/CT in Diagnosing and Characterizing Prostate Cancer (PHASE1)
- PET/CT in Evaluating Response to Chemotherapy in Patients With Breast Cancer (NA)
- Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 5-METHYL-2'-FLUOROARAURACIL F-18 CI brief — competitive landscape report
- 5-METHYL-2'-FLUOROARAURACIL F-18 updates RSS · CI watch RSS